Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

• Main Authors: Tony Mok, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Chong Jen Yu, Sumitra Thongprasert, Jennifer Sandoval-Tan, Jin Soo Lee, Fatima Fuerte, David S. Shames, Barbara Klughammer, Matt Truman, Pablo Perez-Moreno, Yi Long Wu
• 格式: 雜誌
• 出版: 2018
• 主題: Biochemistry, Genetics and Molecular Biology; Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84966701371&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/55172

© 2016 The Authors. Objectives: The FASTACT-2 study of intercalated erlotinib with chemotherapy in Asian patients found that EGFR mutations were the main driver behind the significant progression-free survival (PFS) benefit noted in the overall population. Further exploratory biomarker analyses were...